Skip to main content

Table 7 Post-treatment changes of lymphocytes and immunoglobulins

From: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

 

Baseline values and post-treatment percent change from baseline (mean ± SD)

 

Baseline

6 weeks

10 weeks

18 weeks

32 weeks

Lymphocytes

N = 14

N = 6

N = 8

N = 9

N = 11

   B cells

123 ± 160 cells/μl

-35% ± 23%

-41% ± 41%

-34% ± 23%

-44% ± 21%

   T cells

744 ± 554 cells/μl

+16% ± 80%

+28% ± 78%

+47% ± 109%

+17% ± 69%

Immunoglobulins

 

N = 12

N = 14

N = 10

N = 11

   IgG

1,252 ± 355 mg/dl

+3% ± 8%

+5% ± 13%

+5% ± 9%

1% ± 13%

   IgA

226 ± 94 mg/dl

+3% ± 11%

+8 ± 13%

+5% ± 12%

+10% ± 20%

   IgM

117 ± 73 mg/dl

-12% ± 18%

-1% ± 23%

-6% ± 19%

-9% ± 9%

  1. SD, standard deviation.